REVOLUTION MEDICINES INC (1RVMD.MI) Stock Price & Overview

BIT:1RVMDUS76155X1000

Current stock price

83 EUR
-17 (-17%)
Last:

The current stock price of 1RVMD.MI is 83 EUR. Today 1RVMD.MI is down by -17%.

1RVMD.MI Key Statistics

Market Cap
16.046B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-4.38
Dividend Yield
N/A

1RVMD.MI Stock Performance

Today
-17%
1 Week
N/A
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1RVMD.MI Stock Chart

REVOLUTION MEDICINES INC / 1RVMD Daily stock chart

1RVMD.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1RVMD.MI.


Chartmill TA Rating
Chartmill Setup Rating

1RVMD.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to 1RVMD.MI. While 1RVMD.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1RVMD.MI Earnings

Next Earnings DateMar 2, 2026
Last Earnings DateNov 5, 2025
PeriodQ3 / 2025
EPS Reported-$1.61
Revenue Reported
EPS Surprise -11.24%
Revenue Surprise -100.00%

1RVMD.MI Forecast & Estimates

27 analysts have analysed 1RVMD.MI and the average price target is 100.64 EUR. This implies a price increase of 21.25% is expected in the next year compared to the current price of 83.

For the next year, analysts expect an EPS growth of -59.94% and a revenue growth 1279.08% for 1RVMD.MI


Analysts
Analysts87.41
Price Target100.64 (21.25%)
EPS Next Y-59.94%
Revenue Next Year1279.08%

1RVMD.MI Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

1RVMD.MI Financial Highlights

Over the last trailing twelve months 1RVMD.MI reported a non-GAAP Earnings per Share(EPS) of -4.38. The EPS decreased by -44.01% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-600.09M
Industry RankSector Rank
PM (TTM) N/A
ROA -26.65%
ROE -37.58%
Debt/Equity 0.16
Chartmill High Growth Momentum
EPS Q2Q%-71.28%
Sales Q2Q%N/A
EPS 1Y (TTM)-44.01%
Revenue 1Y (TTM)-100%

1RVMD.MI Ownership

Ownership
Inst Owners100.45%
Shares193.32M
Float186.18M
Ins Owners1.85%
Short Float %N/A
Short RatioN/A

About 1RVMD.MI

Company Profile

1RVMD logo image Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Company Info

IPO: 2020-02-13

REVOLUTION MEDICINES INC

700 Saginaw Dr

Redwood City CALIFORNIA US

Employees: 809

1RVMD Company Website

1RVMD Investor Relations

Phone: 13026365400

REVOLUTION MEDICINES INC / 1RVMD.MI FAQ

What does REVOLUTION MEDICINES INC do?

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).


What is the current price of 1RVMD stock?

The current stock price of 1RVMD.MI is 83 EUR. The price decreased by -17% in the last trading session.


Does 1RVMD stock pay dividends?

1RVMD.MI does not pay a dividend.


How is the ChartMill rating for REVOLUTION MEDICINES INC?

1RVMD.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the employee count for 1RVMD stock?

REVOLUTION MEDICINES INC (1RVMD.MI) currently has 809 employees.


What is REVOLUTION MEDICINES INC worth?

REVOLUTION MEDICINES INC (1RVMD.MI) has a market capitalization of 16.05B EUR. This makes 1RVMD.MI a Large Cap stock.